Bionano Genomics (NASDAQ:BNGO) Trading Down 1.3% – Here’s What Happened
by Teresa Graham · The Cerbat GemShares of Bionano Genomics, Inc. (NASDAQ:BNGO – Get Free Report) were down 1.3% on Friday . The company traded as low as $1.5750 and last traded at $1.58. Approximately 95,903 shares traded hands during trading, a decline of 28% from the average daily volume of 133,750 shares. The stock had previously closed at $1.60.
Analysts Set New Price Targets
BNGO has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target (down from $11.00) on shares of Bionano Genomics in a report on Monday, November 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Bionano Genomics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.50.
Check Out Our Latest Analysis on Bionano Genomics
Bionano Genomics Price Performance
The company has a 50 day moving average of $1.61 and a 200-day moving average of $2.45. The stock has a market capitalization of $16.08 million, a P/E ratio of -0.33 and a beta of 1.14. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.07.
Bionano Genomics (NASDAQ:BNGO – Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.22. The firm had revenue of $7.37 million during the quarter, compared to analyst estimates of $6.91 million. Bionano Genomics had a negative net margin of 134.36% and a negative return on equity of 86.36%.
Bionano Genomics Company Profile
Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.